Active — Not RecruitingPhase 2

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

United States, Hong Kong, Malaysia169 participantsStarted 2021-02-08

Plain-language summary

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have no evidence of progression by neurologic symptoms or signs for at least 4 weeks prior to the first dose.
✓. Participants with previously treated brain metastases may participate provided they have stable central nervous system (CNS) disease for at least 4 weeks prior to enrollment. Stable CNS disease is defined as resolution of all neurologic symptoms to baseline, having no evidence of new or enlarging brain metastases, and not requiring use of corticosteroids for CNS disease for at least 14 days prior to the start of study treatment. Participants who have had brain metastases resected or have received whole brain radiotherapy ending at least 4 weeks (or stereotactic radiotherapy ending at least 2 weeks) prior to initiation of study treatment are permitted.
✓. Carcinomatous meningitis is excluded regardless of clinical stability.

What they're measuring

Progression-free Survival (PFS)

Timeframe: From randomization until death from any cause (up to 7 years)

Trial details

NCT IDNCT04736173

SponsorArcus Biosciences, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-05

View on ClinicalTrials.gov More Non Small Cell Lung Cancer trials